Review3 Biotech2025
Recent advances in nanomedicine for the diagnosis and therapy of thyroid disorders.
Review in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Nanoparticles in Thyroid Autoimmunity: Diagnostic and Therapeutic Applications.Journal of clinical medicine · 2026Review
- Modulation of cell migration and invasion of thyroid cancer cells using miRNA-enriched extracellular vesicles.Frontiers in endocrinology · 2026Article
- Nanoformulated Phytochemicals Against Pancreatic Cancer: Emerging Advances in Therapeutic Strategies.International journal of nanomedicine · 2026Review
- Theranostic Potentials of Metallic Nanoparticles in Thyroid Diseases: Challenges and Prospects.International journal of nanomedicine · 2026Review
- Therapeutic Potential of Glucose Oxidase-Loaded Biogenic Mesoporous Silica Nanoparticles in Ovarian Cancer.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid diseases, including hypo- or hyperthyroidism and thyroid cancer, are among the most prevalent endocrine disorders that remain challenging to diagnose accurately, and conventional treatments have low therapeutic efficacy. Recently, a wide variety of innovations in the area of nanomedicine, including nanotechnology-based quick and portable diagnostic tools and targeted delivery of pharmaceutics for thyroid disorders, are looking extremely promising. Hence, this review elaborates on the pathogenesis of thyroid disorders and the unique composition, structural attributes, synthesis methodologies, and surface design of nanoplatforms, focusing on the three principal application domains of nanomedicine in thyroid disorders: nanodiagnosis, nanotherapy, and nanotheranostics. Subsequently, cutting-edge studies featuring a series of notable and noteworthy accomplishments are comprehensively summarized, highlighting the intrinsic interaction between nanomedicines and thyroid dysfunctions; particular emphasis is placed on the biosafety of nanomedicines, which seeks to facilitate the future clinical translation of this emerging discipline. This comprehensive review concludes by identifying potential challenges and future perspectives of nanomedicine for the diagnosis and therapy of thyroid disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.